KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Net Margin: 2010-2025

Historic Net Margin for TherapeuticsMD (TXMD) over the last 15 years, with Sep 2025 value amounting to 13.01%.

  • TherapeuticsMD's Net Margin rose 2069.00% to 13.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.19%, marking a year-over-year decrease of 3260.00%. This contributed to the annual value of 7.44% for FY2024, which is 20552.00% up from last year.
  • TherapeuticsMD's Net Margin amounted to 13.01% in Q3 2025, which was up 1,964.29% from 0.63% recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Net Margin ranged from a high of 36,538.51% in Q2 2022 and a low of -4,481.44% during Q1 2022.
  • In the last 3 years, TherapeuticsMD's Net Margin had a median value of -4.33% in 2025 and averaged -397.35%.
  • Its Net Margin has fluctuated over the past 5 years, first soared by 3,672,394bps in 2022, then plummeted by 3,709,091bps in 2023.
  • Over the past 5 years, TherapeuticsMD's Net Margin (Quarterly) stood at 268.50% in 2021, then tumbled by 22,584bps to 42.66% in 2022, then skyrocketed by 8,842bps to 131.08% in 2023, then tumbled by 11,039bps to 20.69% in 2024, then skyrocketed by 2,069bps to 13.01% in 2025.
  • Its last three reported values are 13.01% in Q3 2025, 0.63% for Q2 2025, and -4.33% during Q1 2025.